ASRM Presentation Now Available: Anti-Müllerian Hormone (AMH) as a Therapeutic Target in Women’s Health

Written By Sarah Faranda

For decades, Anti-Müllerian Hormone (AMH) was seen only as a marker of ovarian reserve. David Pepin’s groundbreaking research is changing that narrative, unlocking AMH’s potential as a therapeutic target for: 

  • Contraception 

  • Fertility preservation 

  •  Menopause management 

At ASRM, Pepin shared how AMH could redefine women’s health for generations to come. You can now watch his full presentation here.  

 “One of the most exciting frontiers in this field is Anti-Müllerian Hormone… By harnessing this mechanism to protect the ovarian reserve, we can explore applications in contraception, menopause, Oncofertility, and assisted reproduction,” says Evan Sussman, CEO, Granata Bio Corporation  

For more information on Granata Bio’s mission to innovate in reproductive health, view our pipeline.

Sarah Faranda
Next

Is There an End in Sight to Reproductive Health's Drug Innovation Drought?